SIPA1L2

Across TCGA pan-cancer cohorts, SIPA1L2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SIPA1L2 data layer compared with 27 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SIPA1L2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SIPA1L2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

UCEC, LUAD, and CCRCC are the cancer types where SIPA1L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Quartile	All	1.000	0.809	.014	16	view →
LUAD	DFS	Median	All	0.883	0.522	.015	12	view →
CCRCC	OS	Quartile	II,III,IV	0.393	0.823	.023	9	view →
HNSC	DFS	Tertile	All	1.000	0.899	.004	9	view →
PDAC	OS	Median	II,III,IV	0.457	0.205	.022	6	view →
LSCC	DFS	Median	II,III,IV	0.999	0.837	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SIPA1L2–UCEC (OS)

Open the UCEC breakdown →